Management of Sertraline‑Induced Tachycardia and Beta‑Blocker Therapy in Hyperadrenergic POTS

1. Sertraline‑related tachycardia in POTS

Sertraline can worsen tachycardia in patients with post‑ural tachycardia syndrome (POTS) and should be considered for discontinuation; bisoprolol is an appropriate pharmacologic option for hyperadrenergic POTS (but not specifically for mitigating sertraline side‑effects)【1】.
Medications that inhibit norepinephrine re‑uptake (including sertraline’s weak noradrenergic activity) should be avoided in POTS because they increase sympathetic drive and aggravate tachycardia【1】.
The half‑life of sertraline is ≈ 26 h, with complete elimination expected 5–7 days after cessation【2】.
Tachycardia amplification is especially pronounced in POTS patients who already exhibit a hyperadrenergic state【2】【3】.

Hyperadrenergic POTS – defined by standing heart rate > 120 bpm, elevated plasma catecholamines, tremor, and anxiety – responds to beta‑blockade (e.g., bisoprolol)【3】【4】.
Neuropathic POTS – characterized by peripheral denervation without catecholamine excess – is treated with midodrine 2.5–10 mg three times daily【1】.
Hypovolemic POTS – marked by low intravascular volume – is managed with fludrocortisone 0.1–0.3 mg once daily【1】.

Beta‑blockers are not indicated for reflex‑mediated syncope but are specifically beneficial for hyperadrenergic POTS【1】.
They should be prescribed only for the hyperadrenergic phenotype; indiscriminate use is discouraged【1】.
The most studied agents are propranolol and atenolol, with atenolol typically dosed 25–100 mg daily【1】.

Begin bisoprolol at a low dose (2.5–5 mg once daily) and titrate slowly while monitoring heart rate【3】.
Target a standing heart‑rate increase < 30 bpm and avoid excessive resting bradycardia【4】.

Before starting bisoprolol: obtain a resting ECG, measure supine and standing blood pressure and heart rate, and check electrolytes (potassium, magnesium)【1】【4】.
During therapy: regularly assess standing heart rate, symptom improvement, and watch for over‑reduction of heart rate; monitor for supine hypertension when vasoconstrictors (e.g., midodrine) are co‑administered【1】.
Contraindications to bisoprolol: classic orthostatic hypotension (≥ 20/10 mmHg drop within 3 min)【3】【5】, resting bradycardia【1】, and concurrent intravenous calcium‑channel blocker therapy (risk of additive hypotension/bradycardia)【1】.

Co‑administration requires close monitoring of heart rate and blood pressure because bisoprolol lowers rate while sertraline may raise it in POTS patients【1】.
If heart rate reaches ≈ 180 bpm, a cardiac evaluation should be performed to exclude other arrhythmias【1】.

Increase fluid intake to 2–3 L per day and salt intake to 6–10 g per day (unless contraindicated by heart failure, hypertension, or renal disease)【1】.
Use waist‑high compression stockings and implement a structured exercise program【1】.

All statements are supported by the cited references; strength of evidence was not explicitly graded in the source material.